Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

805
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
805
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The inaugural HEMA report: a missed opportunity for comprehensive value assessment.

Journal of comparative effectiveness research·2026
Same author

Patient engagement in managed care pharmacy: Putting policy into practice.

Journal of managed care & specialty pharmacy·2025
Same author

The Association of the 340B Program with Affordable Care Act (ACA) Premiums: A Longitudinal Analysis from 2018 to 2022.

Inquiry : a journal of medical care organization, provision and financing·2025
Same author

The time is now: Addressing health inequities in the workforce.

Journal of managed care & specialty pharmacy·2025
Same author

The time is now: Addressing health inequities in the workforce.

Journal of managed care & specialty pharmacy·2025
Same author

Improving access to gene therapies: a holistic view of current challenges and future policy solutions in the United States.

Journal of comparative effectiveness research·2024

Related Experiment Video

Updated: Mar 2, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K

Why Value Framework Assessments Arrive at Different Conclusions: A Multiple Myeloma Case Study.

Kimberly Westrich1, Lisabeth Buelt1, Robert W Dubois1

  • 11 National Pharmaceutical Council, Washington, DC.

Journal of Managed Care & Specialty Pharmacy
|May 24, 2017
PubMed
Summary

Value assessment frameworks for medical treatments vary significantly, leading to inconsistent evaluations for therapies like multiple myeloma. This variability impacts healthcare decisions for patients, providers, and payers.

More Related Videos

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.8K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

Related Experiment Videos

Last Updated: Mar 2, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.8K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

Area of Science:

  • Health economics and outcomes research
  • Biopharmaceutical value assessment
  • Healthcare policy analysis

Background:

  • The U.S. healthcare system is shifting from volume-based to value-based care.
  • Emerging value assessment frameworks aim to guide decisions for patients, providers, and payers.
  • These frameworks can influence patient care, provider pathways, and payer coverage decisions.

Purpose of the Study:

  • To analyze the variability in value determinations across prominent U.S. healthcare value assessment frameworks.
  • To examine how different frameworks assess the value of treatment regimens for multiple myeloma.
  • To explore the reasons behind discrepancies in value assessments and their implications for healthcare decision-making.

Main Methods:

  • Cross-framework comparison of prominent U.S. value assessment tools.
  • Case study analysis of multiple myeloma treatment regimens.
  • Examination of consistency in value findings across different frameworks.

Main Results:

  • Significant variability exists in how different value assessment frameworks determine the value of medical treatments.
  • Multiple myeloma treatment assessments showed inconsistencies across frameworks, including those from ASCO, ICER, MSKCC, and NCCN.
  • Differences in evidence, methodology, and intended use contribute to divergent value conclusions.

Conclusions:

  • The substantial variability in value assessment frameworks raises concerns about their readiness to support consistent healthcare decision-making.
  • Understanding the drivers of these discrepancies is crucial for improving the reliability and utility of value assessments.
  • Further alignment and transparency in value assessment methodologies may be needed to ensure equitable patient access to therapies.